Literature DB >> 26524376

Quantitative benefit-risk assessment by MCDA of the quadrivalent HPV vaccine for preventing anal cancer in males.

Lydie Marcelon1, Thomas Verstraeten1,2, Geraldine Dominiak-Felden1, François Simondon1.   

Abstract

OBJECTIVES: To quantify the benefit-risk (BR) balance of the quadrivalent human papillomavirus (qHPV) vaccine for use in males, including anal cancer prevention, by using the multicriteria decision analysis (MCDA).
METHODS: Value tree and an effect table were compiled using relevant qHPV vaccine efficacy/safety data. An expert panel validated the final model inputs.
RESULTS: On a scale of 0-100, the MCDA qHPV vaccine score (66) was superior to the no vaccination score (46), indicating a more favorable BR balance for the qHPV vaccine. Significant changes in weight of individual outcomes were needed to change BR balance in sensitivity analyses. The qHPV vaccine maintained a better BR profile in all alternative models.
CONCLUSIONS: MCDA can be used to transparently evaluate BR balance of vaccines. The qHPV vaccine had a favorable BR balance in males. Including anal cancer as a new indication further improves the BR profile of the qHPV vaccine.

Entities:  

Keywords:  Benefit-risk assessment; anal cancer; human papillomavirus (HPV); multicriteria decision analysis; vaccine

Mesh:

Substances:

Year:  2015        PMID: 26524376     DOI: 10.1586/14760584.2016.1107480

Source DB:  PubMed          Journal:  Expert Rev Vaccines        ISSN: 1476-0584            Impact factor:   5.217


  5 in total

1.  A novel measure of drug benefit-risk assessment based on Scale Loss Score.

Authors:  Gaelle Saint-Hilary; Veronique Robert; Mauro Gasparini; Thomas Jaki; Pavel Mozgunov
Journal:  Stat Methods Med Res       Date:  2018-07-20       Impact factor: 3.021

2.  A comparison of various aggregation functions in multi-criteria decision analysis for drug benefit-risk assessment.

Authors:  Tom Menzies; Gaelle Saint-Hilary; Pavel Mozgunov
Journal:  Stat Methods Med Res       Date:  2022-01-19       Impact factor: 3.021

Review 3.  Structured benefit-risk evaluation for medicinal products: review of quantitative benefit-risk assessment findings in the literature.

Authors:  Marie-Laure Kürzinger; Ludivine Douarin; Ievgeniia Uzun; Chantal El-Haddad; William Hurst; Juhaeri Juhaeri; Stéphanie Tcherny-Lessenot
Journal:  Ther Adv Drug Saf       Date:  2020-12-08

4.  Multi-Criteria Decision Analysis for Benefit-Risk Analysis by National Regulatory Authorities.

Authors:  Orin Chisholm; Patrick Sharry; Lawrence Phillips
Journal:  Front Med (Lausanne)       Date:  2022-01-12

5.  Benefit-Risk Monitoring of Vaccines Using an Interactive Dashboard: A Methodological Proposal from the ADVANCE Project.

Authors:  Kaatje Bollaerts; Tom De Smedt; Katherine Donegan; Lina Titievsky; Vincent Bauchau
Journal:  Drug Saf       Date:  2018-08       Impact factor: 5.606

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.